CT 365Alternative Names: CT365
Latest Information Update: 25 Aug 2016
At a glance
- Originator HEC Pharm
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Solid tumours
Most Recent Events
- 25 Aug 2016 Preclinical trials in Idiopathic pulmonary fibrosis in China (unspecified route) (HEC Pharm pipeline, August 2016)